Comparison of letrozole with gonadotropins and letrozole_gonadotropin combination for ovulation induction in PCOS women after clomiphene citrate failure

Bushra M. Majeed
Department of Obstetric and gynecology, College of medicine, University of Tiktit, Tiktit, Iraq

Received 1/10/2012  Accepted 8/12/2012

Abstract
The aim of this study is to compare the efficacy of letrozole with gonadotropin and letrozole plus gonadotropin for ovulation induction in PCOS women after clomiphene citrate failure, Seventy eight women with PCO failed to conceive with clomiphene citrate divided in to three groups A,B,C treated with letrozole tablet, letrozole plus follicular stimulating hormone and follicular stimulating hormone injection alone respectively for ovulation induction..Results: ovulation rate was (65.4%), (76.9%) and (76.9%) in group A,B &C respectively, pregnancy rate in study groups were (50%), (69.2%)and(65.4%) in A,B,&C respectivelyConclusion: Letrozole appears to be a suitable ovulation inducing agent in PCOS women with CC failure and significant higher pregnancy rate was observed in letrozole co treatment with gonadotropins as compared to other two protocoles

Key ward: Letrozole , follicular stimulating hormone, infertile women, PCOS
Introduction
Polycystic ovary syndrome is a silent epidemic; leading cause of infertility in women due to anovulation Syndrome. 20-25% of Polycystic ovary syndrome women are resistant to clomiphene citrate and fail to ovulate, in such cases the traditional option is to administer gonadotropins. The concept of using aromatase inhibitors (AIs) as a new method of ovulation induction has been extensively investigated by several research groups in the past few years. During the past decade, Letrozole has been successfully used for induction of ovulation in an ovulatory patient with Polycystic ovary syndrome (PCOS) and for augmentation of ovulation in ovulatory women. Letrozole a highly selective AIs has been found to be effective in inducing ovulation in anovulatory and ovulatory infertile women with inadequate response to clomiphene citrate. Several studies revealed that Letrozole can be used as an alternative to clomiphene citrate for superovulation in patient with unexplained infertility. Letrozole is as effective as clomiphene citrate in inducing ovulation, but is devoid of antiestrogenic side effects, result in lower serum estrogen concentrations and is associated with good pregnancy rate and potentially a lower incidence multiple pregnancy than clomiphene citrate. When combined with gonadotropins for assisted reproductive technologies (ART) Letrozole reduced the dose of FSH required for optimal follicle recruitment and improve the response to FSH in poor responders. Because of relatively long half-life of clomiphene citrate isomers, clomiphene citrate may exert un avoidable antiestrogenic effects on peripheral estrogen targets (endocervix and endometrium) that likely explain the absence of pregnancy despite ovulation observed in some CC treated patients. Letrozole co treatment was shown to be more cost-effective than FSH alone in patients undergoing controlled ovarian stimulation and intrauterine insemination. As a result of the mechanism of action of AIs, the present study proposed that AIs could be used alone for induction of ovulation or as adjuvant in conjunction with exogenous FSH or other medications to improve the outcome of ovarian induction.

Patients and Method
A prospective study, including 78 infertile women with PCOS diagnosed by the
Rotterdam criteria\(^{(20)}\) who failed to conceive or ovulate despite 3 cycles of clomiphene citrate using 100mg/day and showed poor endometrial development (endometrial thickness \(\leq 0.7\) cm) were seen in Tikrit teaching hospital between July 2010 to March 2012. In this study the treatment protocol was planned in to three groups: **Group A:** 26 women received letrozole 2.5mg twice daily starting from day 3 of menstrual cycle for 5 days. **Group B:** 26 women received letrozole 2.5mg twice daily and two ampoules of 75IU of follicle-stimulating hormones on day 3 and other on day 8 of cycle. **Group C:** 26 women were continuously received one ampule of 75IU follicular stimulating hormones daily from day 2 of cycle onwards until the day of HCG administration.

All patients were monitored by ovarian follicular development and endometrial thickness by transvaginal ultrasound from day 8 onward, 10,000IU HCG administered as a single dose when average diameter of follicles reach \(\geq 18\) mm. Tubal patency and male partner semen were evaluated, the patients were counseled about the benefit and the risks of Letrozole and gonadotropins treatment. Ovulation rate and pregnancy rate were compared amongst the three groups.

**Results**

The age of patients ranged from 21 to 38 years with a mean 26.8 years. (28.2\%) with primary infertility \&(71.8\%) with secondary infertility, the duration of infertility was ranged from 3-9 years. Ovulation rate and pregnancy rate were lower in primary infertility than in secondary infertility as shown in tables (2),(3).

### Table (1):- Method of work

<table>
<thead>
<tr>
<th>Study groups</th>
<th>No.</th>
<th>Type of drug</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group A</strong></td>
<td>26</td>
<td>Letrozole tablet</td>
<td>2.5mg twice daily</td>
</tr>
<tr>
<td><strong>Group B</strong></td>
<td>26</td>
<td>Letrozole tab+Gonadotropin (FSH)</td>
<td>2.5mg twice daily &amp; tow Gonadotropin ampuleS 75IU</td>
</tr>
<tr>
<td><strong>Group C</strong></td>
<td>26</td>
<td>Gonadotropin ampoules(FSH)</td>
<td>*Gonadotropin ampoules 75IU</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>78</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The ovulation rate was 65.4%, 76.9%, and 76.9% in group A, B, & C respectively. Ovulation rate was similar in Letrozole plus FSH and FSH on cycle, while pregnancy rate was more in Letrozole plus FSH group. We found that pregnancy rate in study groups were (50%), (69.2%) and (65.4%) in A, B, & C respectively.

Table (2):- Ovulation rate in study groups

<table>
<thead>
<tr>
<th>Type of infertility</th>
<th>Ovulation</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td>Yes</td>
<td>5(71.4%)</td>
<td>5(71.4%)</td>
<td>6(75%)</td>
<td>16(72.7%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>2(28.6%)</td>
<td>*2(28.6%)</td>
<td>2(75%)</td>
<td>6(27.3%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>7(100%)</td>
<td>7(100%)</td>
<td>8(100%)</td>
<td>22(100%)</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td>YES</td>
<td>12(63.2%)</td>
<td>15(78.9%)</td>
<td>14(77.7%)</td>
<td>41(73.2%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>7(36.8%)</td>
<td>4(21.1%)</td>
<td>4(22.3%)</td>
<td>15(26.8%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>19(100%)</td>
<td>19(100%)</td>
<td>18(100%)</td>
<td>56(100%)</td>
</tr>
</tbody>
</table>

Table (3):- Pregnancy rate in study groups

<table>
<thead>
<tr>
<th>Type of infertility</th>
<th>Pregnancy</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td>Yes</td>
<td>3(42.8%)</td>
<td>4(57.2%)</td>
<td>6(75%)</td>
<td>13(59%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>4(57.2%)</td>
<td>3(42.8%)</td>
<td>2(75%)</td>
<td>9(41%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>7(100%)</td>
<td>7(100%)</td>
<td>8(100%)</td>
<td>22(100%)</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td>YES</td>
<td>10(52.6%)</td>
<td>14(73.6%)</td>
<td>10(55.5%)</td>
<td>35(62.5%)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>9(47.4%)</td>
<td>5(26.4%)</td>
<td>8(44.5%)</td>
<td>21(37.5%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>19(100%)</td>
<td>19(100%)</td>
<td>18(100%)</td>
<td>56(100%)</td>
</tr>
</tbody>
</table>
We have three cases of multiple pregnancy one case triplet and two cases of twin pregnancy. All of third group C (continues FSH)

Discussion
Several investigators have documented the feasibility, safety and effectiveness of aromatase inhibition for ovulation induction. Casper has stated that Letrozole has a potential role as a first line oral therapy for ovulation inductions in women with PCOS. The pregnancy rate in present study was 50%, 69.2% & 65.4% and ovulation rate was 65.4%, 76.9% & 76.9% in group A, B, and C respectively. This is good agreement with recent reports which conclude that letrozole has a better ovulation and pregnancy rate in patients with PCOS. There are significantly higher pregnancy rates reported with gonadotropin than with letrozole alone. Several studies revealed that the combination of exogenous gonadotropins with Letrozole increase the number of mature oocytes and therefore improve the outcome of IUI cycle. The addition of gonadotropins to Letrozole is accompanied by a more ovarian response than the use of Letrozole alone, this may be attributed to the fact that Letrozole temporarily inhibit the production of estrogen which activates gonadotropin and in turn stimulates follicular growth. Letrozole administration in early follicular phase blocks estrogen synthesis, and causes temporary accumulation of androgens in ovarian follicles, the accumulation of androgens may increase the sensitivity of the growing follicles to FSH by increasing the expression of FSH receptors. In the present study gonadotropin alone or in combination with letrozole appears to be the most effective protocol, and pregnancy rate in group B (Letrozole & FSH) was observed to be slightly higher as compared to group C (FSH). This consist with Goswami et al. There were no multiple gestation cases among pregnancies that occurred with letrozole and letrozole FSH co treatment, this consist with Mitwally et al.

Conclusion
Letrozole appears to be a suitable ovulation inducing agent in PCOS women with CC failure and significant higher pregnancy rate was observed in letrozole co treatment with gonadotropins as compared to other two protocols.

Recommendation
Letrozole co treatment with gonadotropins best ovulation protocol for infertile PCOS woman after clomiphene citrate protocol failure.

References
2. Elnashar A, Fouad H, Eldosoky M, Saeid N. Letrozole induction of ovulation in women with clomiphene citrate-resistant Polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteizing hormone/follicle-stimulating hormone ratio. Fertil Steril. 2006; 85: 511-3.
5. Barrosog G, Menocal G, Felix H, Rojas-Ruiz JC. Comparison of the efficacy of the aromatase inhibitor Letrozole and...
clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovulation hyperstimulation. Fert Steril 2006;86:1428-31


